



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s)	Minotti et al.	Examiner:	Unassigned
Serial No.:	10/728,015	Group Art Unit:	1623
Confirmation No:	Unassigned	Docket:	LD0226 DIV (1188-37 RCE/DIV)
Filed:	December 4, 2003	Dated:	March 2, 2004
For:	METHOD FOR REDUCING TOXICITY OF COMBINED CHEMOTHERAPIES		

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

*I hereby certify this correspondence is being deposited
with the United States Postal Service as first class mail,
postpaid in an envelope, addressed to:
Commissioner for Patents, P.O. Box 1450,
Alexandria, Virginia 22313-1450
on March 2, 2004*

Signed: *MJ Mullin / M.J. Mullin*

INFORMATION DISCLOSURE STATEMENT

Sir:

In order to fulfill the requirements of candor and good faith set forth in 37 C.F.R. §1.56, Applicants submit herewith the following Information Disclosure Statement in accordance with the provisions of 37 C.F.R. §1.97 and §1.98.

Attached hereto is a Form PTO-1449 listing references which may be considered material in evaluating the patentability of the claims of the subject application. The subject application is a division of U.S. Application No. 09/954,953, and all of the listed references were cited in the prosecution of the parent application. Pursuant to 37 C.F.R. §1.98(d) and the PTO's waiver of

the requirement under 37 C.F.R. §1.98(a)(2)(i) (1276 OG 55), no copies of the listed references are being submitted herewith.

If the Examiner has any questions or comments relating to the present application, he or she is respectfully invited to contact Applicants' attorney at the telephone number set forth below.

Respectfully submitted,

A handwritten signature in cursive script, appearing to read "Christina Warrick", is written over a horizontal line.

Christina Warrick
Registration No.: 45,690
Attorney for Applicant(s)

Please direct correspondence to:
Stephen B. Davis, Esq.
BRISTOL-MYERS SQUIBB COMPANY
P.O. Box 4000
Princeton, NJ 08543-4000



FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Rev. 2-32) PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO. 1188-37 RCE/DIV	SERIAL NO. 10/728,015
	APPLICANT Minotti et al.	CONFIRMATION NO.
	FILING DATE December 4, 2003	GROUP 1623

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
		4,203,900	05/20/90	Kaiser			
		4,206,221	06/03/90	Miller et al.			
		4,303,439	12/01/81	Howe et al.			
		4,354,029	10/12/82	Kaiser et al.			
		4,360,678	11/23/82	Howe et al.			
		4,443,611	04/17/84	Kaiser			
		4,543,414	09/24/85	Carson			
		4,743,700	05/10/88	Jamm et al.			
		4,814,470	03/21/89	Colin et al.			
		4,857,653	08/15/89	Colin et al.			
		4,876,399	10/24/89	Holton et al.			
		4,877,881	10/31/89	Belliotti et al.			
		4,924,002	05/08/90	Kostlan			
		4,924,011	05/08/90	Denis et al.			
		4,924,012	05/08/90	Colin et al.			
		4,942,184	07/17/90	Haugwitz et al.			

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
(Rev. 2-32) PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.
1188-37 RCE/DIV

SERIAL NO.
10/728,015

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

APPLICANT
Minotti et al.

CONFIRMATION NO.

(Use several sheets if necessary)

FILING DATE
December 4, 2003

GROUP
1623



		4,960,790	10/02/90	Stella et al.			
		5,015,744	05/14/91	Hotan			
		5,059,699	10/22/91	Kingston et al.			
		5,128,478	07/07/92	Ito et al.			
		5,136,060	08/04/92	Holtan			
		5,194,635	03/16/93	Kingston et al.			
		5,208,237	05/04/93	Hewawasam et al.			
		5,227,400	07/13/93	Holton et al.			
		5,243,045	09/07/93	Holton et al.			
		5,254,580	10/19/93	Chen			
		5,264,591	11/23/93	Bombardelli et al.			
		5,272,171	12/21/93	Ueda et al.			
		5,278,324	01/11/94	Kingston et al.			
		5,283,253	02/01/94	Holton et al.			
		5,296,506	03/22/94	Kingston			
		5,319,112	06/07/94	Kingston et. al.			
		5,352,806	10/04/94	Gunawardana et al.			
		5,399,726	03/21/95	Holton et al.			

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
(Rev. 2-32) PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.
1188-37 RCE/DIV

SERIAL NO.
10/728,015

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

APPLICANT
Minotti et al.

CONFIRMATION NO.

(Use several sheets if necessary)

FILING DATE
December 4, 2003

GROUP
1623



		5,420,337	05/30/95	Patel et al.			
		5,440,056	08/08/95	Klein et al.			
		5,449,790	09/12/95	Zheng et al.			
		5,468,769	11/21/95	Klein et al.			
		5,476,954	12/19/95	Borzat et al.			
		5,556,878	09/17/96	Kelly et al.			
		5,580,997	12/02/96	Bouchard et al.			
		5,589,502	12/31/96	Tsujihara et al.			
		5,616,739	04/01/97	Mas et al.			
		5,618,952	04/08/97	Holton et al.			
		5,621,121	04/15/97	Cammercon et al.			
		5,635,531	06/03/97	Chen			
		5,637,732	06/10/97	Holton et al.			
		5,646,176	07/08/97	Golik et al.			
		5,670,658	09/23/97	Bastart			
		5,677,470	10/14/97	Tsujihara et al.			
		5,710,287	01/20/98	Holton et al.			
		5,721,268	02/24/98	Holton et al.			

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
(Rev. 2-32) PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.
1188-37 RCE/DIV

SERIAL NO.
10/728,015

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT


APPLICANT
Minotti et al.

CONFIRMATION NO.

(Use several sheets if necessary)

FILING DATE
December 4, 2003

GROUP
1623



		5,728,687	03/17/98	Bissery			
		5,728,725	03/17/98	Holton et al.			
		5,760,252	06/02/98	Holton et al.			
		5,767,296	06/16/98	Terasawa et al.			
		5,773,461	06/30/98	Wittma et al.			
		5,808,102	09/15/98	Poss et al.			
		5,840,931	11/24/98	Bouchard et al.			
		5,847,170	12/08/98	Bouchard et al.			
		5,889,043	03/30/99	Bouchard et al.			
		5,908,835	06/01/99	Bissery			
		6,005,120	12/21/99	Holton et al.			
		6,020,507	02/01/00	Gibson			
		6,043,375	03/28/00	Borzat et al.			
		6,072,060	06/06/00	Suidell et al.			
		6,096,909	08/01/00	Ojima			
		6,100,411	08/08/00	Ojima			
		6,214,863	04/10/01	Bissery			
		6,239,167	05/29/01	Bissery			

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
(Rev. 2-32) PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.
1188-37 RCE/DIV

SERIAL NO.
10/728,015

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

APPLICANT
Minotti et al.

CONFIRMATION NO.

(Use several sheets if necessary)

FILING DATE
December 4, 2003

GROUP
1623

		6,248,908	06/01	Kant			
		6,340,701	01/02	Chari et al.			
		6,353,120	03/02	Kant			

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION	
							YES	NO
		JP 55-145650	11/13/80	Japan				
		JP 61-005022	01/10/86	Japan				
		JP 61-51578	11/10/86	Japan				
		JP 60-222416	11/07/85	Japan				
		JP61-115022	06/02/86	Japan				
		JP 9208572A	08/12/97	Japan				
		WO 90/02738	03/22/90	PCT				
		WO 92/09589	06/11/92	PCT				
		WO 92/19765	11/12/92	PCT				
		WO 94/07876	04/14/94	PCT				
		WO 94/13655	06/23/94	PCT				
		WO 94/14787	07/07/94	PCT				

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.



FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
(Rev. 2-32) PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.
1188-37 RCE/DIV

SERIAL NO.
10/728,015

APPLICANT
Minotti et al.

CONFIRMATION NO.

FILING DATE
December 4, 2003


GROUP
1623

		WO 95/03265	02/02/95	PCT				
		WO 96/00724	01/11/96	PCT				
		WO 96/13495	05/09/96	PCT				
		WO 96/14309	05/17/96	PCT				
		WO 96/23779	08/08/96	PCT				
		WO 97/09979	03/20/97	PCT				
		WO 97/23472	07/03/97	PCT				
		WO 97/32578	09/12/97	PCT				
		WO 97/32869	09/12/97	PCT				
		WO 98/01435	01/15/98	PCT				
		WO 98/22451	05/28/98	PCT				
		WO 99/33462	07/08/99	PCT				
		EP 0 359 516 B1	08/10/94	EPO				
		EP 0 400 971 B1 & A3	07/29/98	EPO				
		EP 0 428 376 B1	01/10/96	EPO				
		EP 0 505 047 B1 & A1	04/24/96	EPO				
		EP 0 537 905 B1 & A1	03/06/96	EPO				
		EP 0 604 910 A1	07/06/04	EPO				

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.



FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
(Rev. 2-32) PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.
1188-37 RCE/DIV

SERIAL NO.
10/728,015

APPLICANT
Minotti et al.

CONFIRMATION NO.

FILING DATE
December 4, 2003

GROUP
1623

		1,061,330	08/28/79	Canada				
		1,695,918	05/06/71	German				
		2,919,891	12/04/80	German				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		Donnelli, M.G., et al; Pharmacokinetics of anticancer agents in patients with impaired liver function; European Journal of Cancer; Pergamon Press; Oxford, Great Britain; vol. 34, no. 1; January 1998
		ECCO: Taxol/doxorubicin Improves Survival in Metastatic Breast Cancer; Doctor's Guide, 'Online!', 22 September 1999; retrieved from the Internet: www.pslgroup.com/dg/13144a.htm ; retrieved 2002-11-06.
		DG Dispatch - ECCO: New Drug Combination Enhances Treatment for Advanced Breast Cancer; Doctor's Guide; 'Online!'; 19 September 1999; retrieved from the Internet: www.pslgroup.com/dg/12c452.htm .
		Sparano, "Doxorubicin/Taxane combinations: Cardiac toxicity and pharmacokinetics." Seminars in Oncology, Vol. 26, No. 3, Suppl. 9 (June 1999), pages 14-19.
		Gianni et al., "Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel patients with breast cancer." Journal of clinical oncology, vol. 15, no. 5 (May 1997) pages 1906-1915.
		Zoli et al. "In vitro activity of taxol and taxotere in comparison with doxorubicin and cisplatin on primary cell cultures of human breast cancers." Breast Cancer Research and Treatment, 34, 1995, pages 63-39.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
(Rev. 2-32) PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.
1188-37 RCE/DIV

SERIAL NO.
10/728,015

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

APPLICANT
Minotti et al.

CONFIRMATION NO.

(Use several sheets if necessary)

FILING DATE
December 4, 2003

GROUP
1623

Wahl et al. "Selective tumor sensitization to taxanes with the mab-drug
conjugate CBR96-doxorubicin." Abstract: Int. J. Cancer vol. 4 (15 Aug.
2001), pages 590-600.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.